Primus Pharmaceuticals, Inc. Patent Application Trends in 2024

Primus Pharmaceuticals, Inc. Patent Filing Activity

Primus Pharmaceuticals, Inc. patent applications in 2024

Error creating thumbnail: File missing

Top 10 Technology Areas

A61K31/421 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 2 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]
A61K9/2018 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]
A61P25/02 (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS)
- Count: 1 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]
A61P29/00 (Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID])
- Count: 1 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]
A61K9/0053 (Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations)
- Count: 1 patents
- Example: 20240216340. REDUCED DOSE METAXALONE FORMULATIONS simplified abstract (Primus Pharmaceuticals, Inc.)
A61K9/2013 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20240216340. REDUCED DOSE METAXALONE FORMULATIONS simplified abstract (Primus Pharmaceuticals, Inc.)
A61K9/4858 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20240216340. REDUCED DOSE METAXALONE FORMULATIONS simplified abstract (Primus Pharmaceuticals, Inc.)

Emerging Technology Areas

A61K9/4858 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20240216340. REDUCED DOSE METAXALONE FORMULATIONS simplified abstract (Primus Pharmaceuticals, Inc.)
A61K9/2013 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20240216340. REDUCED DOSE METAXALONE FORMULATIONS simplified abstract (Primus Pharmaceuticals, Inc.)
A61K9/0053 (Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations)
- Count: 1 patents
- Example: 20240216340. REDUCED DOSE METAXALONE FORMULATIONS simplified abstract (Primus Pharmaceuticals, Inc.)
A61P29/00 (Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID])
- Count: 1 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]
A61P25/02 (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS)
- Count: 1 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]
A61K9/2018 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]
A61K31/421 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 2 patents
- Example: [[20240197687. METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE simplified abstract (Primus Pharmaceuticals, Inc.)]]